Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin Versus Placebo for Septic Shock Refractory to High Doses Catecholamine Vasopressors
NCT04339868Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Mar 2025
- Countries
- 1
- Sponsor
- Mahidol University
- Modality
- Peptides, Small Molecules
- Drugs
- terlipressin
- Conditions
- septic shock
01
Overview
Phase 2, randomised, double-blind trial in septic shock comparing Terlipressin group with Placebo group (2 arms). Primary endpoint: Achieve target blood pressure with low dose adrenergic agents at 6 hours. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Terlipressin group
Terlipressin acetate 20-100 mcg/hr plus standard of care (norepinephrine/epinephrine)
Placebo group
Placebo (0.9% NaCl) plus standard of care (norepinephrine/epinephrine)
03
Who it enrols
Patients with septic shock refractory to high-dose norepinephrine (>= 0.2 mcg/kg/min) or norepinephrine plus epinephrine, with MAP < 65 mmHg or lactate > 2 mmol/L, excluding those with severe cardiac conditions, end-stage renal or liver disease, or refractory malignancies.
04
Endpoints
Primary
Achieve target blood pressure with low dose adrenergic agents
Secondary
28 day mortality
Mean arterial blood pressure
Hospital mortality
ICU mortality
Beyond the preview
Go deeper on NCT04339868.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339868.